Merck
MRK
Market cap $198B

85.20 USD

+0.49

0.58%

At close Apr 30, 4:00 PM EDT

After hours

85.00

-0.20

0.23%

1 day

0.58%

5 days

8.84%

1 month

-5.08%

3 months

-13.90%

6 months

-18.73%

Year to date

-14.09%

1 year

-34.07%

5 years

7.39%

10 years

43.05%

About: Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.

Employees: 75,000

Healthcare Drug Manufacturers - General

0

Funds holding %

of 7,425 funds

0

Analysts bullish %

of 7 analysts

Fund manager confidence

Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)

75% more first-time investments, than exits

New positions opened: 357 | Existing positions closed: 204

15% more call options, than puts

Call options by funds: $1.8B | Put options by funds: $1.56B

2% more funds holding

Funds holding: 3,441 [Q3] → 3,519 (+78) [Q4]

2.09% more ownership

Funds ownership: 75.57% [Q3] → 77.66% (+2.09%) [Q4]

10% less capital invested

Capital invested by funds: $217B [Q3] → $196B (-$21.1B) [Q4]

17% less repeat investments, than reductions

Existing positions increased: 1,295 | Existing positions reduced: 1,555

36% less funds holding in top 10

Funds holding in top 10: 111 [Q3] → 71 (-40) [Q4]

See Fund Rankings

Research analyst outlook

7 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$85

0%

upside

Avg. target

$105

23%

upside

High target

$115

35%

upside

7 analyst ratings

3 positive

43%

4 neutral

57%

0 negative

0%

Cantor Fitzgerald Carter Gould 39% 1-year accuracy 12 / 31 met price target	0%downside $85	Neutral Initiated	22 Apr 2025
Guggenheim Vamil Divan 40% 1-year accuracy 12 / 30 met price target	35%upside $115	Buy Reiterated	17 Apr 2025
Deutsche Bank James Shin 40% 1-year accuracy 2 / 5 met price target	23%upside $105	Hold Downgraded	18 Feb 2025
B of A Securities Tim Anderson 47% 1-year accuracy 7 / 15 met price target	31%upside $112	Buy Maintained	5 Feb 2025
BMO Capital Evan David Seigerman 28% 1-year accuracy 5 / 18 met price target	13%upside $96	Market Perform Maintained	5 Feb 2025

See Analyst Rankings

Financial journalist opinion

Based on 211 articles about MRK published over the past 30 days

Healthy Returns: Here are the drugmakers with new U.S. investments as Trump's pharma tariffs loom

Tariff threats are fueling a new wave of U.S. manufacturing investments from the pharmaceutical industry.

Healthy Returns: Here are the drugmakers with new U.S. investments as Trump's pharma tariffs loom

The Motley Fool

Should Investors Buy Merck Stock After These Huge Risks?

The performance of healthcare companies is relatively uncorrelated with broader macroeconomic growth.

Should Investors Buy Merck Stock After These Huge Risks?

The Motley Fool

Stock Market Crash: 3 High-Yielding Dividend Stocks Near Their 52-Week Lows to Buy Right Now

One great thing about a crash or downturn in the markets is that it can allow you to go bargain hunting fairly easily. Many stocks have been falling this year, and if you're a dividend investor, you know that means yields are rising as a result.

Stock Market Crash: 3 High-Yielding Dividend Stocks Near Their 52-Week Lows to Buy Right Now

3 Names I Picked Up In The Latest Market Slump

When the market is reaching toward all-time highs, I tend to start building a cash pile. When the market starts to get quite volatile and brings declines, that can create opportunities for putting some of that cash to work. With April's market slump, putting cash to work is exactly what I was doing; today, we are looking at 3 of the names that I added to during this market decline.

3 Names I Picked Up In The Latest Market Slump

Merck to invest $1B in new US plant to make blockbuster cancer treatment Keytruda

The new facility will produce biologic drugs and Keytruda, becoming Merck's first in-house US site to make the blockbuster cancer treatment, the company said.

Merck to invest $1B in new US plant to make blockbuster cancer treatment Keytruda

Merck Breaks Ground on New $1 Billion Biologics Center of Excellence in Wilmington, Delaware

RAHWAY, N.J.--(BUSINESS WIRE)--Merck Breaks Ground on New $1 billion Biologics Center of Excellence in Wilmington, Delaware.

Merck Breaks Ground on New $1 Billion Biologics Center of Excellence in Wilmington, Delaware

Merck to invest $1 billion in new Delaware plant to boost US manufacturing, WSJ reports

U.S. drugmaker Merck is investing $1 billion in a new Delaware plant to expand its domestic production as it prepares to deal with the looming impact from President Donald Trump's tariffs, the Wall Street Journal reported on Tuesday.

Merck to invest $1 billion in new Delaware plant to boost US manufacturing, WSJ reports

Merck will build a $1 billion plant to expand U.S. manufacturing as tariff threats loom

The Delaware facility will ensure a domestic supply of biologic drugs including the cancer drug Keytruda.

Merck will build a $1 billion plant to expand U.S. manufacturing as tariff threats loom

Zacks Investment Research

Should You Buy, Sell or Hold MRK Stock After Q1 Earnings Beat?

We believe investors with a long-term horizon should stay invested in MRK stock, while short-term investors may exit the stock.

Should You Buy, Sell or Hold MRK Stock After Q1 Earnings Beat?

2 Must-Own Dividends At Bargain Basement Prices

April's market volatility has created dividend bargains, allowing investors to pick high-quality blue-chip stocks with strong balance sheets and long-term return potential. Merck, trading at a low P/E of 9.3 and yielding 4.1%, carries a strong late-stage pipeline of 20 drugs. Schlumberger, with a P/E of 10.2 and a 3.3% yield, offers resilient growth prospects in offshore production and digital solutions.

2 Must-Own Dividends At Bargain Basement Prices

See News Rankings

Charts implemented using Lightweight Charts™